Business

The late-stage failure of AstraZeneca's Wainua (eplontersen) in the Phase 3 CARDIO-TTRansform trial is a first-in-class setback for TTR gene-silencing therapies in…

Alnylam Pharmaceuticals (ALNY) is up 3.6% today. Here is some analysis on what might have caused this price movement.Analysis: The move appears tied to a mix of…

DelveInsight's "AL Amyloidosis Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of the AL amyloidosis,…

"We are excited to acquire a royalty interest in cliramitug," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "Cliramitug…

As AstraZeneca exited the first quarter, initially skeptical analysts were coming around to the potential for the drugmaker to hit its goal of growing sales to $80…

Royalty Pharma has secured a stake in another transthyretin-mediated (ATTR) amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the…

ROLE SUMMARYThe Medical Engagement, Strategy & Insights Director provides senior scientific and medical expertise in Transthyretin Amyloid Cardiomyopathy (ATTR-…

What's going on here?BofA Securities just got more cautious on Alnylam’s heart-drug story, trimming its peak sales view to $11.8 billion and cutting its price…

The global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market was valued at USD 5.85 billion in 2025 and is projected to reach USD 64.09 billion by 2033, growing…

Austin, United States, July 07, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Transthyretin Amyloidosis Treatment Market was valued at USD 8.95 Billion in…